Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of K1-70 in Japanese Patients with Active Thyroid Eye Disease
jRCT2031240330Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of K1-70 in Graves Orbitopathy (GO) (4 arms), sponsored by GSK. Primary endpoint: Proptosis Improvement Rate at Week 24. Started Oct 2024; status: active, not recruiting.
02
Drugs
K1-70
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2031240330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240330.